SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-052681
Filing Date
2022-04-29
Accepted
2022-04-29 06:01:51
Documents
7
Period of Report
2022-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223510-1_def14a.htm DEF 14A 1146283
2 GRAPHIC lg_ymabsthera-4c.jpg GRAPHIC 74814
3 GRAPHIC sg_thomas-bw.jpg GRAPHIC 4788
4 GRAPHIC tm223510d1-pxy_proxy1bw.jpg GRAPHIC 341226
5 GRAPHIC tm223510d1-pxy_proxy2bw.jpg GRAPHIC 511173
6 GRAPHIC tm223510d1-pxy_proxy3bw.jpg GRAPHIC 678598
7 GRAPHIC tm223510d1-pxy_proxy4bw.jpg GRAPHIC 602256
  Complete submission text file 0001104659-22-052681.txt   4195431
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38650 | Film No.: 22869800
SIC: 2834 Pharmaceutical Preparations